FDA CBER Updates
The latest guidances, approvals, and safety alerts from FDA CBER, curated by automated regulatory intelligence.
Recommends risk-reduction measures to minimize the likelihood of transfusion-transmitted hepatitis B virus (HBV) in blood and blood components.
Establishes FDA expectations for potency assurance across the lifecycle of cellular and gene therapy products, with an emphasis on linking product…
Provides draft FDA CBER guidance on how sponsors of individualized human genome editing products should structure BLA submissions and plan for postapproval…
Clarifies FDA CBER expectations for ensuring the suitability of blood and blood component donors, including quarantine/hold requirements for source plasma, to…
Blood pressure and pulse donor eligibility requirements may be updated through this CBER compliance policy, shaping how establishments qualify donors used for…
Provides recommendations to support consistent, controlled blood collection, processing, and storage when manufacturing blood components using the buffy coat…
Clarifies FDA expectations for potency assessment strategies for active immunotherapy products, which may influence how sponsors design potency assays and…
Clarifies FDA CBER’s expectations for developing potential cellular and gene therapy products, emphasizing coordinated planning across manufacturing (CMC)…
Provides FDA CBER recommendations for evaluating blood donor eligibility and deferring potentially exposed donors in response to Ebola virus, along with…
Discusses how FDA may consider and leverage prior knowledge when developing human gene therapy products that incorporate genome editing, potentially…
Clarifies expectations for submitting continuous glucose monitoring (CGM) data from clinical trials to support review of endpoints and analyses in FDA…
Introduces Chemistry, Manufacturing, and Controls (CMC) flexibility approaches for developing human cellular and gene therapy products intended to support a…
Topic: Status: Draft.
Topic: Status: Draft.
Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval; Draft Guidance for Industry…
Clarifies the processes for bioresearch monitoring inspections to ensure compliance with FDA regulations, emphasizing the importance of adherence to Good…
Outlines comprehensive recommendations for the inclusion and reporting of QTc information in labeling for human prescription drugs and biological products to…
Clarifies submission pathways for cross-center master files across various FDA centers, enhancing inter-center communication and efficiency.
FDA releases draft guidance on CMC requirements for gene therapy products, addressing manufacturing complexity and quality control.
Topic: Status: Draft.